跳至主要内容
临床试验/NCT05363020
NCT05363020已完成4 期

S-Adenosyl-L-Methionine (SAMe) vs Placebo for Discomfort and Functional Limitations Associated With Osteoarthritis of the Hands: a Pilot Study

Dartmouth-Hitchcock Medical Center1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年8月17日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
40
试验地点
1
主要终点
Determine the effect of SAMe supplements on hand discomfort relative to placebo, as measured by the change in discomfort scores over time on a visual analog scale

研究概览

简要总结

The primary objective of this study is to demonstrate the feasibility of evaluating SAMe tolerability, analgesic benefits, and daily functional improvement in patients with osteoarthritis of the hands compared to placebo. The secondary objective of this study is to generate preliminary data on discomfort, function, quality of life in patients with osteoarthritis of the hands when taking SAMe compared to placebo.

详细描述

At week 0, all patients giving written informed consent and meeting eligibility requirements will be randomized in a double-blind manner (participant and investigator) in a 1:1 ratio to SAMe (400mg orally, twice daily) or placebo (400mg, twice daily) for 8 weeks. Followed by a one week wash out period followed by another 8 weeks of SAMe (400mg, twice daily) or placebo (400mg, twice daily) for 8 weeks (whichever was not given during the first 8 week period).

Participants will complete weekly surveys during the entire study regarding hand discomfort, functional limitations and side effects

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Supportive Care
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Current primary care provider within the Dartmouth Health system
  • Office visit at Dartmouth Health in the past 3 years
  • Participants must be 40 or older at the time of signing the informed consent
  • Participants have discomfort or functional limitations of one or both hands AND either:
  • Objective findings of at least one hand meeting diagnostic criteria based on the American College of Rheumatology (ACR)* or
  • Existing radiographic evidence of osteoarthritis as judged by a radiologist
  • Patients taking OTC or prescription analgesics who are willing to stop their current analgesics for two weeks prior to study entry and remain off those medications over the course of the study
  • *Objective inclusion criteria (see poster schematic)
  • Swelling or deformity of 2 of the following ten joints: the 2nd and 3rd distal interphalangeal (DIP) of each hand, the 2nd and 3rd proximal interphalangeal (PIP) of each hand, and the 1st carpometacarpal joints of both hands.

排除标准

  • Patients taking prescription medications other than NSAIDs for their OA who are unable to stop their medication
  • Patients with diagnoses of arthritis from conditions other than OA
  • Patients whose symptomatic joint is an artificial joint
  • Patients with Bipolar Disorder
  • Patients taking any of the following medications at study entry OR starting any of these medications during the study period:
  • daily opioids (including tramadol or buprenorphine)
  • gabapentin or pregabalin
  • Prescription NSAIDs that they are unable to stop or topical diclofenac
  • SNRI drugs (Effexor, Cymbalta, Fetzima, Pristiq)
  • The participant has a condition or is in a situation which, in the investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study

研究组 & 干预措施

S-Adenosyl-L-Methionine (SAMe)

Experimental

Participants receive S-Adenosyl-L-Methionine (SAMe) 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.

干预措施: S-Adenosyl-L-Methionine (Sam-E) (Drug)

S-Adenosyl-L-Methionine (SAMe)

Experimental

Participants receive S-Adenosyl-L-Methionine (SAMe) 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.

干预措施: Placebo (Drug)

Placebo

Placebo Comparator

Participants receive identically appearing 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.

干预措施: S-Adenosyl-L-Methionine (Sam-E) (Drug)

Placebo

Placebo Comparator

Participants receive identically appearing 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.

干预措施: Placebo (Drug)

结局指标

主要结局

Determine the effect of SAMe supplements on hand discomfort relative to placebo, as measured by the change in discomfort scores over time on a visual analog scale

时间窗: Weekly for 17 weeks

Scores range from 0-10, 0 being no discomfort and 10 being maximum discomfort

次要结局

  • Determine the effect of SAMe supplementation on quality of life measures regarding hand arthritis, as measured by DASH (Disability of Arm, Shoulder and Hand) survey responses done weekly for 17 weeks(Weekly for 17 weeks)
  • Determine tolerability of SAMe supplementation compared to placebo, as measured by a survey of 14 common symptoms one may experience from a supplement(Weekly for 17 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Scott C. Jaynes

Physician Investigator

Dartmouth-Hitchcock Medical Center

研究点 (1)

Loading locations...

相似试验